Lundbeck Shifts Investment Focus to U.S. and China Amid European Challenges

Lundbeck has announced a strategic shift in its capital investment focus, prioritizing the U.S. and China over Europe. Bloomberg posted on X, highlighting the company's decision as Europe grapples with increasing pressure to stimulate innovation. This move reflects Lundbeck's response to the evolving economic landscape and the need to adapt to regions with more favorable conditions for growth. The pharmaceutical company aims to leverage opportunities in the U.S. and China, where market dynamics and regulatory environments are perceived as more conducive to innovation and expansion. Lundbeck's decision underscores the challenges faced by European markets in maintaining competitiveness and fostering a supportive environment for business development.